1387PDifferences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumours (NETs)
In: Annals of oncology, Jg. 30 (2019), Heft 5
Online
serialPeriodical
Zugriff:
Titel: |
1387PDifferences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumours (NETs)
|
---|---|
Autor/in / Beteiligte Person: | Hernando Cubero, J ; Grande, E ; Castellano Gauna, D ; Ibrahim, T ; Fazio, N ; Lopez, C ; Teulé, A ; Valle, J W ; Alonso, V ; Molina-Cerrillo, J ; Tafuto, S ; Custodio, A ; Trejo, L ; Casteras, A ; Manneh Kopp, R ; Miqueo, C ; Roca Herrera, M ; Garcia-Carbonero, R ; Salazar, R ; Capdevila, J |
Link: | |
Zeitschrift: | Annals of oncology, Jg. 30 (2019), Heft 5 |
Veröffentlichung: | 2019 |
Medientyp: | serialPeriodical |
ISSN: | 0923-7534 (print) |
Sonstiges: |
|